Research has indicated that testosterone, though at a much lower concentration, is also normal to the female physiology, and older women may suffer from androgen deficiency, resulting in loss of energy, depression, impairment of sexual functioning, and headaches. Returning testosterone levels to normal female physiological values, in combination with existing estradiol therapy, has been found beneficial. We intend to tap into this market with low testosterone release from our formulations.
HIV-infected men with low testosterone levels have been associated with statistically significant gains in lean body mass (p=0.02), increased red cell counts, and improvements in emotional distress. Transdermal testosterone has also been administered to HIV-positive women, yielding positive trends in weight gain, improvements in bone density and quality of life.
HIV treatments have successfully incorporated testosterone as a supplement to decrease the loss of body mass brought about by the disease. Currently, other than the gels, few of the other available treatments are included in this regimen. Inclusion of a convenient oral supplement to improve lean body mass in the form of testosterone would be considered highly beneficial.
Recent reports have also linked hypogonadism with Metabolic Syndrome (MS) and Insulin Resistance (IR) in general populations. These are large markets and currently no reliable estimates are available. In addition, several recent reports have also linked adverse cardiovascular events to low testosterone levels.
TesoRx closes Series A funding round.